The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Myeloproliferative neoplasm, unclassifiable (MPN-U) is a heterogeneous disease, which despite clinical presentation and histological phenotype consistent with MPN does not meet diagnostic criteria for any of the defined MPN variants such as polycythemia vera or essential thrombocythemia. Genetically, the most common driver is a JAK2 V617F mutation, but mutations in CALR, MPL, and ‘triple-negative’ cases have also been implicated.1 Patients with this rare subset of MPN (< 5% of all MPN cases) have worse outcomes compared to patients with other forms of MPN. There is currently no accepted standard therapeutic regimen and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the only potentially curative options, although outcomes have not been fully investigated.
In order to better understand the outcome of allo-HSCT in patients with MPN-U Donal P. McLornan, and colleagues, on behalf of Chronic Malignancies Working Party of the EBMT, performed a retrospective, multicenter study, which was recently published in the British Journal of Hematology.2
Analysis of overall survival (OS), non-relapse mortality (NRM), and relapse incidence was performed on the data from the EBMT transplant database. Adult patients who underwent first allo-HSCT for MPN-U, between the years 2000 and 2015, using reduced-intensity conditioning (RIC) or myeloablative conditioning (MAC) were eligible.
Table 1. Patient characteristics
MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; TBI, total body irradiation |
|||
Characteristics |
MAC (n = 31) |
RIC (n = 39) |
p value |
---|---|---|---|
Median age, years (range) |
52.2 (21.9–69.7) |
58.8 (31.3–69.7) |
0.002 |
Median time to transplant, months (range) |
10.58 (2.86–148.5) |
16.03 (3.32–244.21) |
0.306 |
Conditioning regimens, % TBI-based Fludarabine and busulphan Fludarabine and melphalan Busulphan and cyclophosphamide Other |
42 22 – 10 26 |
– 56 8 – 36 |
– |
Donor type Matched related Unrelated |
45 55 |
33 67 |
0.313 |
In vivo T cell depletion, % Yes No Unknown |
52 35 13 |
72 20 8 |
0.113 |
Table 2. Outcomes
CI, confidence interval; GvHD, graft-versus-host disease; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; |
|||
Characteristics |
MAC (n = 31) |
RIC (n = 39) |
p value |
---|---|---|---|
Neutrophil engraftment < 30 days, % Yes No Unknown |
97 3 0 |
82 15 3 |
0.086 |
GvHD, % (95% CI) Acute at 3 months, Grade ≥2 Chronic at 12 months |
37 (19–54) 52 (32.4–71.6) |
16 (4–28) 32.1 (14.8–49.4) |
0.05 0.17 |
Cumulative incidence of relapse, % (95% CI) 1-year 3-year 5-year |
10 (0–20) 23 (8–37) 27 (11–43) |
28 (14–42) 36 (21–51) 36 (21–51) |
0.28 |
Overall survival rates, % (95% CI) 1-year 3-year 5-year |
77 (62–92) 55 (37–72) 42 (23–60) |
59 (44–74) 44 (28–59) 41 (25–56) |
0.33 |
Results of this largest to date analysis of allo-HSCT outcomes in patients with MPN-U demonstrate the potentially curative role of allo-HSCT in MPN-U and provides for the first time more robust data about engraftment, GvHD, and outcome. The risk of relapse in these patients remains high, and occurs early after transplantation, independent of conditioning regimen.
Although the RIC regimen seems to show a trend for lower aGvHD and cGvHD it is offset by a lower neutrophil engraftment rate. Therefore, the authors recommend using MAC in younger and fit patients and reserve RIC for older patients who can still benefit from allo-HSCT.
However, the authors acknowledge the limitation of the study including, relatively low number of patients, changes in transplantation practice, a lack of comprehensive cytogenetic and mutational status, as well as differences in age, the length of disease, and percentage of in vivo T cell depletion between the cohorts.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content